Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMHMG6X)

Drug Name

SX-682 Drug Info

Synonyms

1648843-04-2; UNII-H5212R2DPM; H5212R2DPM; SX682; (2-(((5-((4-Fluorophenyl)carbamoyl)pyrimidin-2-yl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid; CHEMBL4297480; GTPL10165; BCP32154; EX-A4295; MFCD28502254; s8947; SX 682; SX682; SB17394; HY-119339; CS-0067128; [2-[[5-[(4-fluorophenyl)carbamoyl]pyrimidin-2-yl]sulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid; 2-(2-Dihydroxyboryl-5-trifluoromethoxybenzylsulfanyl)pyrimidine-5-carboxylic acid (4-fluorophenyl)amide; B-(2-(((5-(((4-Fluorophenyl)amino)carbonyl)-2-pyrimidinyl)thio)methyl)-4-(trifluoromethoxy)phenyl)boronic acid; Boronic acid, B-(2-(((5-(((4-fluorophenyl)amino)carbonyl)-2-pyrimidinyl)thio)methyl)-4-(trifluoromethoxy)phenyl)-

Indication

Disease Entry	ICD 11	Status	REF
Melanoma	2C30	Phase 1	[1]
Myelodysplastic syndrome	2A37	Phase 1	[2]

Cross-matching ID

PubChem CID: 90467234
CAS Number: CAS 1648843-04-2
TTD Drug ID: DMHMG6X

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-X-C chemokine receptor type 1 (CXCR1)	TTMWT8Z	CXCR1_HUMAN	Inhibitor	[3]
C-X-C chemokine receptor type 2 (CXCR2)	TT30C9G	CXCR2_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
C-X-C chemokine receptor type 1 (CXCR1)	DTT	CXCR1	4.912	3.858	3.897	3.7
C-X-C chemokine receptor type 2 (CXCR2)	DTT	CXCR2	2.722	1.202	1.202	0.848

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Melanoma

ICD Disease Classification

2C30

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
C-X-C chemokine receptor type 1 (CXCR1)	DTT	CXCR1	1.29E-01	0.12	0.32
C-X-C chemokine receptor type 1 (CXCR1)	DTT	CXCR1	1.66E-01	0.07	0.2
C-X-C chemokine receptor type 2 (CXCR2)	DTT	CXCR2	8.82E-01	-0.23	-0.21
C-X-C chemokine receptor type 2 (CXCR2)	DTT	CXCR2	1.34E-01	0.21	0.19

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT03161431) SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab. U.S. National Institutes of Health.
2	ClinicalTrials.gov (NCT04245397) SX-682 Treatment in Subjects With Myelodysplastic Syndrome Who Had Disease Progression or Are Intolerant to Prior Therapy. U.S. National Institutes of Health.
3	Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clin Cancer Res. 2020 Mar 15;26(6):1420-1431.